Abstract 147P
Background
In 2017, the 8th edition of the Union for International Cancer Control TNM classification (TNM8) was published and clinical staging system was newly defined. Recently, this clinical staging reportedly predicted the prognosis in patients with gastric cancer (GC). Different from common GC, the diagnosis and the treatment of adenocarcinoma of the esophagogastric junction (AEG) have been controversial. Moreover, its incidence also has increased in Japan. The purpose of this study was to clarify whether the prognosis of patients with Siewert type II/III tumors was appropriately stratified by the clinical staging system.
Methods
Patients who were diagnosed with AEG type II/III and received gastrectomy or esophagectomy between 1986 and 2014 at Kanagawa Cancer Center were included in this study. Patients received neoadjuvant chemotherapy were excluded.
Results
A total of 196 patients were examined, 123 (63%) patients had type II tumor and 73 (37%) had type III. 41 patients were classified to clinical stage I, 40 were to stage II, 104 were to stage III, and 11 were to stage IV, respectively. The median follow-up period of the survivors was 58.3 months. The 5-year overall survival rate was 48.8 % in whole cohort and were 82.5% in stage I, 70.0% in stage II, 31.7% in stage III, and 9.1% in stage IV. The hazard ratio to stage I was 1.93 in stage II, 5.68 in stage III, and 11.8 in stage IV, which increased in a stepwise manner with the stage.
Conclusions
The clinical staging system of TNM8 could appropriately stratify the prognosis of the patients with Siewert type II/III tumors.
Clinical trial identification
This study was approved by the institutional review board of Kanagawa Cancer Center. (Epidemiological Study-23).
Editorial acknowledgement
Legal entity responsible for the study
Kanagawa Cancer Center.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
339P - Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation: A phase III study
Presenter: Vikas Talreja
Session: e-Poster Display Session
340P - Omega-3 fatty acids for cancer cachexia in advanced non-small cell lung cancer: A meta-analysis
Presenter: Alfredo Chua
Session: e-Poster Display Session
341P - Relationship between muscle mass and quality of life in breast cancer patients who underwent chemotherapy
Presenter: Andree Kurniawan
Session: e-Poster Display Session
342P - Comparison of 0.25 mg versus 0.75 mg of palonosetron in combination with aprepitant and dexamethasone for prevention of chemotherapy-induced nausea and vomiting following cisplatin-containing chemotherapy in patients with esophageal cancer
Presenter: Satoshi Horasawa
Session: e-Poster Display Session
343P - Head-to-head comparison of palonosetron versus granisetron for prevention of chemotherapy induced nausea and vomiting: Systematic review and meta-analysis
Presenter: Chin-Hung Hsu
Session: e-Poster Display Session
344P - Single-centre analysis of anti-resorptive agent-related osteonecrosis of the jaw in lung cancer patients
Presenter: Kohei Fujita
Session: e-Poster Display Session
345P - Thromboembolic events in brain tumour patients on bevacizumab
Presenter: Gunjesh Singh
Session: e-Poster Display Session
346P - Occurence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer: A hospital-based assessment in Indonesia
Presenter: Susanna Hutajulu
Session: e-Poster Display Session
347P - Histamine blockade with loratadine for prevention of granulocyte-colony stimulating factor (G-CSF)-associated bone pain: A meta-analysis
Presenter: Mel Valerie Ordinario
Session: e-Poster Display Session
348P - Anti-VEGF inhibitors and renal safety in onco-nephrology consortium: Urinary protein/creatinine ratio (VERSiON UP study)
Presenter: Michio Nakamura
Session: e-Poster Display Session